Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest 1 selected

Area of interest

Type

Type

Guidance programme

Showing 1 to 11 of 11

TitleType
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasiaMedical technologies guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430Technology appraisal guidance
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia TS ID 12103Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All